<DOC>
	<DOCNO>NCT00460876</DOCNO>
	<brief_summary>This dose-escalation study aim assess toxicity ( marginally activity ) periocular topotecan patient relapsed-resistant retinoblastoma .</brief_summary>
	<brief_title>Phase I Trial Periocular Topotecan Retinoblastoma</brief_title>
	<detailed_description>Patients bilateral retinoblastoma relapse attempt conservative therapy standard regimen carboplatin , etoposide , vincristine external beam radiotherapy face immediate enucleation single remain eye eligible protocol . Starting dose topotecan 0.5 mg dose escalation do accelerate titration method . Any Grade 3 ocular toxicity grade 4 non ocular toxicity design dose limit toxicity . Grade 2 scleral toxicity consider DLT . In case grade 2 ocular toxicity grade 3 systemic toxicity , escalation dose 0.25 mg. Maximal dose 2 mg .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Group Vb ( Reese Ellsworth ) Relapsed progress carboplatinbased regimen external beam radiotherapy Enucleation contralateral eye Normal renal liver function Presence glaucoma , rubeosis iridis , anterior chamber extension Extraocular disease Adequate follow impossible social reason</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>topotecan</keyword>
	<keyword>periocular</keyword>
	<keyword>chemotherapy</keyword>
</DOC>